Med-Fine Capital
Med-Fine leads Series A for China's Degron Therapeutics
US and China-based biotech player Degron Therapeutics has closed a USD 22m Series A round led by Med-Fine Capital.
LAV leads $50m Series B for China's Lynk Pharma
Lilly Asia Ventures (LAV) has led a $50 million Series B round for Lynk Pharmaceuticals, a China-based drug developer that focuses on small-molecule treatments for autoimmune disease, inflammation, and cancer.